Key result
Intramuscular immunization with ASFV-G-ΔI177L/ΔLVR in domestic pigs maintained high antibody positivity for approximately 2 months with no organ or tissue damage after virulent challenge.
Why the study?
African swine fever virus causes significant economic losses worldwide, and the potential of the live attenuated vaccine candidate ASFV-G-ΔI177L/ΔLVR for protection against highly virulent homologous virus under farm environment changes needed evaluation.
Does intramuscular immunization with ASFV-G-ΔI177L/ΔLVR protect domestic pigs against virulent ASFV challenge and maintain long-term antibodies?
Does intramuscular immunization with ASFV-G-ΔI177L/ΔLVR protect domestic pigs against virulent ASFV challenge and maintain long-term antibodies?
The ASFV-G-ΔI177L/ΔLVR vaccine candidate provides protection against virulent challenge and maintains long-term antibodies in domestic pigs without causing organ damage.
Demonstrates protection against homologous challenge with durable antibodies in pigs; leaves open field efficacy and safety pending larger trials.
African swine fever virus (ASFV) has substantially spread worldwide, resulting in significant economic losses in the swine industry. Despite extensive research, no ASF vaccine has surpassed the effectiveness of live attenuated vaccines. For instance, the live attenuated vaccine ASFV-G-ΔI177L/ΔLVR has demonstrated good efficacy and safety, along with prolonged persistence of ASF antibodies after vaccination. Therefore, we aimed to evaluate its potential for protection against highly virulent homologous ASF viruses based on changes in the farm environment. To this end, we challenged domestic pigs with a virulent field strain of ASFV following intramuscular immunization with ASFV-G-ΔI177L/ΔLVR. We further assessed its genomic stability and long-term antibody persistence in immunized domestic pigs. All vaccinated pigs exhibited high antibody positivity, with higher levels of antibodies observed at the time of challenge. These high ASF vaccine antibodies were maintained for approximately 2 months after vaccination. In addition, no organ or tissue damage was observed in the vaccinated animals. Our findings demonstrate the applicability of this vaccine candidate in the prevention of ASFV infection in the swine industry.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied African Swine Fever. ASFV-G-ΔI177L/ΔLVR was evaluated on Protection against highly virulent homologous ASF viruses, genomic stability, and long-term antibody persistence. Intramuscular immunization with ASFV-G-ΔI177L/ΔLVR in domestic pigs maintained high antibody positivity for approximately 2 months with no organ or tissue damage after virulent challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: